Drug Trial Radar · NCT05141786
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).
Last checked: Nov 19, 2026Latest source record: Dec 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 2021
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Shanghai Miracogen Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-mutated unresectable or metastatic non-small-cell lung cancer (NSCLC).
Conditions
- Non-small- Cell Lung Cancer (NSCLC)
Interventions
MRG002Drug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Baseline to study completion (up to 12 months).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.